Art. -Nr.: HY-13592

HDAC-IN-7

(Synonyms: Chidamide impurity)

Kundenbewertung

Based on 1 Customer Validation

HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.15%
CAS. Nr.: 743420-02-2
Formel: C₂₂H₁₉FN₄O₂
Molecular Weight:390.41

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

HDAC-IN-7 Chemical Structure

CAS. Nr.: 743420-02-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.

Alle HDAC Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	4.11 μM Compound: CS055	Antiproliferative activity against human A375 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
A-375	IC₅₀	4.21 μM Compound: CS055; HBI-8000	Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A-375	IC₅₀	4.77 μM Compound: CS055; HBI-8000	Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
A-375	IC₅₀	6.72 μM Compound: CS055	Antiproliferative activity against human A-375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A-375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
A-375	IC₅₀	7.67 μM Compound: CS055	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
A549	IC₅₀	0.665 μM Compound: Chidamide	Antiproliferative activity against human A549 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 to 72 hrs by MTT assay	[PMID: 28532668]
A549	IC₅₀	11.02 μM Compound: 4; CS055	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
A549	IC₅₀	11.02 μM Compound: CS055; HBI-8000	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A549	IC₅₀	6.81 μM Compound: CS055; HBI-8000	Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
BaF3	IC₅₀	1.5 μM Compound: Chidamide	Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
DLD-1	IC₅₀	>4 μM Compound: 4	Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
DOHH-2	IC₅₀	4.3 μM Compound: Chidamide	Antiproliferative activity against human DOHH-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human DOHH-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
EL4	IC₅₀	5.2 μM Compound: Chidamide	Antiproliferative activity against mouse EL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse EL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
Friend leukemia cell line	IC₅₀	0.5 μM Compound: Chidamide	Antiproliferative activity against mouse Friend leukemia cell line assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse Friend leukemia cell line assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
HCT-116	IC₅₀	0.202 μM Compound: Chidamide	Antiproliferative activity against human HCT116 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 to 72 hrs by MTT assay	[PMID: 28532668]
HCT-116	IC₅₀	1.54 μM Compound: 4	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HCT-116	IC₅₀	1.57 μM Compound: CS055; HBI-8000	Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
HCT-116	IC₅₀	149 μM Compound: CS055	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
HCT-116	IC₅₀	2.28 μM Compound: 4; CS055	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
HCT-116	IC₅₀	2.28 μM Compound: CS055	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HCT-116	IC₅₀	2.28 μM Compound: CS055; HBI-8000	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HCT-116	IC₅₀	2.77 μM Compound: CS055	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
HEK293	IC₅₀	32 μM Compound: Chidamide	Inhibition of recombinant human ERG expressed in HEK293 cells after 9 mins by patch clamp method Inhibition of recombinant human ERG expressed in HEK293 cells after 9 mins by patch clamp method	[PMID: 28532668]
HeLa	IC₅₀	>4 μM Compound: 4	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HeLa	IC₅₀	0.9 μM Compound: CS055; HBI-8000	Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 31003060]
HeLa	IC₅₀	0.9 μM Compound: CS055; HBI-8000	Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay	[PMID: 31103900]
HeLa	IC₅₀	10.97 μM Compound: CS055	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
HeLa	IC₅₀	11.83 μM Compound: CS055	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HeLa	IC₅₀	12.59 μM Compound: CS055; HBI-8000	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HeLa	IC₅₀	14.94 μM Compound: CS055	Antiproliferative activity against human Hela cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Hela cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
HeLa	IC₅₀	3.42 μM Compound: CS055; HBI-8000	Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
HepG2	IC₅₀	>8 μM Compound: 6	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32325365]
HepG2	IC₅₀	11.67 μM Compound: CS055	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
HepG2	IC₅₀	22.65 μM Compound: 4; CS055	Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
HH	IC₅₀	>1 μM Compound: 4	Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HL-60	IC₅₀	0.48 μM Compound: 4	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HL-60	IC₅₀	1.3 μM Compound: Chidamide	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
HuT78	IC₅₀	>1 μM Compound: 4	Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
K562	GI₅₀	0.45 μM Compound: Chidamide	Antiproliferative activity against human K562 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition by MTT assay	[PMID: 32088129]
K562	IC₅₀	0.975 μM Compound: Chidamide	Antiproliferative activity against human K562 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 to 72 hrs by MTT assay	[PMID: 28532668]
K562	IC₅₀	21.3 μM Compound: Chidamide	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 37995564]
KG-1	IC₅₀	0.49 μM Compound: 4	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
L1210	IC₅₀	>10 μM Compound: Chidamide	Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
MCF7	GI₅₀	1.43 μM Compound: Chidamide	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay	[PMID: 32088129]
MDA-MB-231	GI₅₀	2.88 μM Compound: Chidamide	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay	[PMID: 32088129]
MDA-MB-231	IC₅₀	3.41 μM Compound: 4	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
MDA-MB-231	IC₅₀	3.6 μM Compound: 6	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32325365]
MDA-MB-468	IC₅₀	>4 μM Compound: 4	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
MGC-803	IC₅₀	6.44 μM Compound: 4; CS055	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
MGC-803	IC₅₀	6.44 μM Compound: CS055	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
MRC5	IC₅₀	>30 μM Compound: Chidamide	Antiproliferative activity against human MRC5 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 48 to 72 hrs by MTT assay	[PMID: 28532668]
MV4-11	IC₅₀	0.32 μM Compound: Chidamide	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
NB-4	IC₅₀	1.9 μM Compound: Chidamide	Antiproliferative activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
NCI-H1299	IC₅₀	16.26 μM Compound: CS055	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
NCI-H460	IC₅₀	>32 μM Compound: CS055	Antiproliferative activity against human H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
NCI-H460	IC₅₀	13.34 μM Compound: CS055	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
NIH3T3	IC₅₀	2.37 μM Compound: CS055; HBI-8000	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 31003060]
NIH3T3	IC₅₀	2.37 μM Compound: CS055; HBI-8000	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
PC-3	IC₅₀	2.093 μM Compound: Chidamide	Antiproliferative activity against human PC3 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 to 72 hrs by MTT assay	[PMID: 28532668]
Raji	IC₅₀	6.9 μM Compound: Chidamide	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
Ramos	IC₅₀	>10 μM Compound: Chidamide	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
RPMI-8226	IC₅₀	4.19 μM Compound: Chidamide	Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 37995564]
RS4-11	IC₅₀	0.81 μM Compound: Chidamide	Antiproliferative activity against human RS4-11 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human RS4-11 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 37995564]
SMMC-7721	IC₅₀	>26 μM Compound: CS055	Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
SMMC-7721	IC₅₀	>26 μM Compound: CS055; HBI-8000	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
SMMC-7721	IC₅₀	25.59 μM Compound: CS055	Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
SMMC-7721	IC₅₀	8.63 μM Compound: CS055; HBI-8000	Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
U-266	IC₅₀	4.81 μM Compound: Chidamide	Antiproliferative activity against human U-266 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human U-266 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 37995564]
U-937	CC₅₀	5 μM Compound: Chidamide	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 29541372]

In Vitro

HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 743420-02-2
Appearance Solid
Molecular Weight 390.41
Formel C₂₂H₁₉FN₄O₂
Color White to off-white
SMILES

O=C(NC1=CC(F)=CC=C1N)C2=CC=C(CNC(/C=C/C3=CC=CN=C3)=O)C=C2
Synonyms

Chidamide impurity
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 5.83 mg/mL (14.93 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5614 mL

12.8070 mL

25.6141 mL

5 mM

0.5123 mL

2.5614 mL

5.1228 mL

10 mM

0.2561 mL

1.2807 mL

2.5614 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (240 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5614 mL	12.8070 mL	25.6141 mL	64.0352 mL
	5 mM	0.5123 mL	2.5614 mL	5.1228 mL	12.8070 mL
	10 mM	0.2561 mL	1.2807 mL	2.5614 mL	6.4035 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

HDAC-IN-7

Covalent Screening Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

FDA-Approved Anticancer Drug Library

Osteogenesis Compound Library

Off-patent Drug Library

Cysteine Targeted Covalent Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

FDA-Approved Drug Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Help & FAQs

Complete Stock Solution Preparation Table

HDAC-IN-7 Related Classifications

HY-13592 Related Classifications